 |
|
|
| |
Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial
|
| |
| |
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
Isabelle Poizot-Martin1, 2, Eric Bellissant3, 4, Philippe Colson5, 6, Alain Renault3, 4, Lionel Piroth7, Caroline Solas8, 9, Marc Bourliere10, Rodolphe Garraffo11, Philippe Halfon12, Jean-Michel Molina13, 14, and the ANRS HC27 BOCEPREVIH Study Group
1Immuno-Hematological Clinical Unit, Aix Marseille University, APHM Sainte-Marguerite, Marseille, France, 2Inserm U912 (SESSTIM), Marseille, France, 3Department of Clinical Pharmacology, Rennes 1 University, Rennes University Hospital, Rennes, France, 4INSERM 0203 CIC-P Clinical Investigation Centre, Rennes, France, 5Federation de Microbiologie Hospitaliere, Aix Marseille University, AP-HM Timone, Marseille, France, 6URMITE, UM 63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France, 7Infectious Diseases Department, University Hospital, H™pital du Bocage, Dijon, France, 8Department of Pharmacology and Toxicology, Aix Marseille Univ, APHM Timone, Marseille, France, 9CRO2, INSERM U911, Marseille, France, 10Hepatogastroenterology Department, Saint Joseph Hospital, Marseille, France, 11Laboratoire de Pharmacologie, Faculty of Medecine of Nice, H™pital Pasteur, Nice, France, 12Medicine, European Hospital, Marseille, France, 13Infectious Diseases Unit, Assistance Publique H™pitaux de Paris (AP-HP) - Saint-Louis Hospital, Paris, France, 14Paris VII - Denis Diderot University, Paris, France
|
| |
|
|
|
|
|
